Natalizumab for relapsing multiple sclerosis.
Meyer
Michael A
MA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007577:JC Virus / Q000187:drug effects* / Q000302:isolation & purification; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000821:virology*; D051379:Mice; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D011120:Polyomavirus / Q000187:drug effects; D019562:Viral Load; D014766:Viremia
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab